Last reviewed · How we verify
Emend® (Aprepitant)
Aprepitant blocks substance P neurokinin-1 (NK1) receptors in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting.
Aprepitant blocks substance P neurokinin-1 (NK1) receptors in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting. Used for Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy, Prevention of postoperative nausea and vomiting (PONV).
At a glance
| Generic name | Emend® (Aprepitant) |
|---|---|
| Also known as | Emend® |
| Sponsor | CR-CSSS Champlain-Charles-Le Moyne |
| Drug class | NK1 receptor antagonist |
| Target | NK1 receptor (neurokinin-1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Aprepitant is a selective antagonist of human neurokinin-1 (NK1) receptors, which are involved in the emetic reflex. By crossing the blood-brain barrier and binding to NK1 receptors in the chemoreceptor trigger zone and vomiting center, it prevents the transmission of signals that trigger nausea and vomiting, particularly those induced by highly emetogenic chemotherapy agents.
Approved indications
- Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy
- Prevention of postoperative nausea and vomiting (PONV)
Common side effects
- Fatigue
- Constipation
- Diarrhea
- Headache
- Hiccups
Key clinical trials
- Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients (PHASE1)
- Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045) (PHASE4)
- An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects (EARLY_PHASE1)
- Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy (NA)
- Efficacy of Aprepitant (Emend®) in Children (PHASE3)
- Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy (PHASE3)
- HBPL Study of the Impact of the NK1 Antagonist Aprepitant (PHASE2)
- Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Emend® (Aprepitant) CI brief — competitive landscape report
- Emend® (Aprepitant) updates RSS · CI watch RSS
- CR-CSSS Champlain-Charles-Le Moyne portfolio CI